Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience, Desktop Genetics Form CRISPR Partnership

NEW YORK (GenomeWeb) – Twist Bioscience and Desktop Genetics today announced that they have formed a partnership to develop and offer integrated experiment design and DNA synthesis tools to facilitate gene-editing research. 

Under the terms of the deal, Desktop will collaborate with its customers to computationally design sgRNA libraries for CRISPR applications in any cell line. These libraries will then be synthesized by Twist and shipped directly to customers.

Additional terms of the arrangement were not disclosed.

"Through this integrated service, customers will be able to utilize Desktop Genetics' design capabilities for optimized gene editing experiments with concurrent access to unparalleled DNA synthesis through our 10,000-well silicon chip technology," Twist CEO Emily Leproust said in a statement.

"By working with Twist Bioscience, we will be able to extend our services to thousands of customers, providing them with rapid access to the high-quality, high-throughput synthetic DNA needed for their functional genomic screens and CRISPR experiments," Desktop CEO Riley Doyle added.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.